Why Do Academic Centers Fail At Timely Submitting Results to Clinicaltrials.gov? 

Several recent reports have pointed out that while the industry has become increasingly compliant with submitting results of clinical trials to clinicaltrials.gov, the academic centers are way behind. A new reports highlights that it is primarily due to lack of resources and support available to academic centers for doing the same. Posting results to clinicaltrials.gov … Read more

Solutions to Increase Reliability of Clinical Trial Data From Wearable Devices

Data collected from wearable devices contain several sources of “noise” that reduce the reliability of such data in support of clinical/medical claims. A report this week presents a summary of the various factors that contribute to erroneous results and reasonable tips to address them. While the use of wearable devices in clinical trials has almost … Read more

Shkreli Keep Giving Valuable Lessons in the Dirty Secrets of the Drug Industry  

It has been a few years since the infamous Martin Shkreli was in the news. And we have another opportunity to thank him for exposing (unintentionally, of course!) some of the worst secret practices of the drug industry. This time Mr. Shkreli shows how companies can use non-disclosure agreements and exclusivity contracts to artificially keep … Read more

FDA’s Interpretation of HCT/Ps is Subject to Legal Review – Federal Judge

A Federal judge in California ruled that FDA’s interpretation of its own Guidance Documents regarding autologous cell therapy is faulty and hence subject to legal challenge. Specifically, the judge ripped through FDA interpretation of the “same surgical process” exemption for the regulation of Human Cellular and Tissue-based Products (HCT/P). The case in point was a … Read more

When FDA Plays God, Patients and Doctors Need to Step Up

The patients and doctors expect FDA to approve products based only on credible scientific data, but a few cases have shown that FDA does not always do that. In those cases, it falls on patients and their doctors to make sensible decisions based on facts before embarking on uncertain therapies carrying astronomical price tags.  FDA … Read more

Is FDA in Trouble: NY Times Thinks So 

FDA is approving new drugs and medical devices too fast, its reviewers are leaving for jobs in the industry they regulate, and it is critically short on resources, the editors of the New York Times opined this week. Another article this week in the Journal of American Medical Association (JAMA) by Harvard researchers, raised similar … Read more